What is in the KLOW peptide blend

KLOW peptide, component by component

KLOW peptide is not a molecule. It is four molecules weighed into one vial: GHK-Cu at 50mg, KPV at 10mg, BPC-157 at 10mg and TB-500 at 10mg, 80mg of material in total. Fifty of those eighty milligrams are GHK-Cu, which is why the vial looks the way it does, and why any single figure offered for the whole blend is mostly a figure about one component. The KLOW 80mg blend is sold as one item and documented as four.

Nothing about the four is interchangeable. They differ in length, in mass and in class. Read as a list of trade names the blend looks like one product. Read as four sequences it is four separate objects that happen to share a cake.

The table below is the whole specification in one grid. Three of the four are also sold here as single-compound vials, and their CAS numbers come from those catalogue entries. KPV is the exception: it is not stocked on its own, so no CAS is published for it here, and the only way to obtain it from this catalogue is inside a KLOW peptide vial.

Two numbers in that table are worth pausing on, because competing listings frequently get them wrong. TB-500 is seven residues, not forty-three. Forty-three is the residue count of thymosin beta-4, the full-length protein the fragment corresponds to, and a specification sheet that prints 43 against a line reading TB-500 has quoted the parent instead of the material. The second is KPV's molecular weight, which several listings leave blank. It is 342.44 g/mol, and it follows directly from the sequence: lysine, proline and valine sum to 378.47 g/mol as free amino acids, and joining them into a chain releases two molecules of water, 36.03 g/mol, leaving C16H30N4O4 at 342.44.

KPV: three residues taken from the end of a hormone

KPV is the smallest thing in a KLOW peptide vial and the least often explained. It is three amino acids, lysine, proline and valine, and it is almost always introduced with the same phrase: the C-terminal tripeptide of alpha-MSH. That phrase is doing a lot of work for a reader who has not met it before, so it is worth unpacking.

A peptide chain has two ends and they are not equivalent. Every amino acid carries an amino group at one end of itself and a carboxyl group at the other, and a chain is assembled by joining one to the next in a fixed direction. What is left unjoined at the start is a free amino group, the N-terminus. What is left unjoined at the finish is a free carboxyl group, the C-terminus. Sequences are written N-terminus first by convention, which is why GEPPPGKPADDAGLV and Ac-LKKTETQ both read left to right in that direction, and why the acetyl cap on TB-500 is written at the front.

So the C-terminal tripeptide of alpha-MSH means the last three residues of that hormone: the tail end of the chain, not the head. Alpha-melanocyte-stimulating hormone is a thirteen-residue peptide hormone of the melanocortin family, a family whose members are cut from the same precursor protein and share stretches of sequence with one another. Its thirteenth, twelfth and eleventh residues, read back from the end, are valine, proline and lysine. KPV is those final three residues made as a molecule in their own right rather than cleaved from a parent. Same residues, same order, none of the chain that normally sits in front of them.

There is a chemical detail here that most write-ups skip, and it is the one that stops KPV and the tail of alpha-MSH from being quite the same object. Alpha-MSH is amidated at its C-terminus: the terminal carboxyl group is capped as an amide rather than left free. KPV supplied as a research material is ordinarily the free acid, with that terminal carboxyl open. Same three residues, different terminal chemistry, and the difference shows up where terminal chemistry always shows up: in exact mass, in charge at a given pH, and therefore in retention time on a reversed-phase column. It is also why an identity confirmation by mass spectrometry is worth having rather than assuming: the free acid at 342.44 and its amide, about a gram per mole lighter, are not the same measurement.

The rest of the distinction matters more than it sounds. A tripeptide is a far smaller and simpler object than the full-length hormone its sequence was taken from, and the two are not the same material in any respect that a laboratory cares about: mass, solubility, stability in solution, behaviour on a column. A short synthetic fragment is also straightforward to build to a defined sequence by solid-phase peptide synthesis and unambiguous to confirm by mass spectrometry, which is a large part of why fragments of longer hormones end up as research materials at all.

Being small has a documentary consequence as well. KPV is 10mg of an 80mg vial, the joint-smallest fill in the blend, and it is the line on the certificate with the least mass standing behind it. On all three of the lots tabulated further down it comes in under its nominal 10mg. Whether that matters depends entirely on what is being asked of the material, and it is knowable at all only because the certificate reports the component rather than the vial. That is the habit of reading set out in how to read a peptide certificate of analysis.

KPV is also the reason KLOW peptide exists as a separate product. GLOW peptide is the same blend without it: three components, 70mg. Adding KPV is what takes the blend to four components and 80mg. Less obviously, it is also what takes the certificate from three assays to four.

Why the KLOW peptide powder is blue

Most single-compound peptide vials hold a white or off-white cake. KLOW peptide holds a blue one, and the reason is copper.

GHK-Cu is not a peptide sitting next to a copper salt. It is a complex: the glycyl-histidyl-lysine tripeptide coordinates a copper(II) ion, and the 403.94 g/mol quoted for the compound is the mass of the whole complex, peptide and metal together. Free GHK is colourless and the copper(II) complex is blue, and there is 50mg of that complex in an 80mg vial, more by mass than the other three components put together.

Colour is therefore a composition signal rather than decoration. A blue lyophilized cake is what a blend built on a copper complex should look like; a white one would not be, and a blue cake in a vial labelled for a compound containing no metal would not be either. It is the crudest identity check available and it costs nothing to make before anything else is done. What a cake should look like in general, blue or white, is covered in the note on lyophilized powder.

Appearance is also a stated specification rather than an observation somebody made in passing. Every published KLOW certificate carries an appearance line, and on all three released lots it reads the same: blue lyophilized powder. That gives the line its only useful property: something to disagree with. A specification that says nothing cannot be failed.

It has one practical consequence for everything done afterwards. Every judgement made by eye on this material, the appearance of the cake and the clarity of the solution once bacteriostatic water has been added, is being made against a coloured background rather than a colourless one. Clear here means clear blue, and particulate matter has to be looked for against that.

Why 80mg on a KLOW peptide label is not a composition

The split described on this page, 50:10:10:10, is the specification this product is made to. It is not a standard. There is no monograph for KLOW peptide, no pharmacopoeial entry, no reference method that defines what the name means, and nothing stops a different supplier from filling an 80mg vial in a different proportion and calling it the same thing. The name travels; the composition does not travel with it.

That makes the total mass the least informative number on any KLOW peptide listing. Eighty milligrams is a weight, not a formula. An 80mg vial could be 50:10:10:10, or 20:20:20:20, or 65:5:5:5, and every one of those is honestly describable as an 80mg four-peptide blend. The figure that carries information is the per-component split, and the figure that carries proof is the per-component measured content on a certificate tied to a lot.

This is the gap most of the category leaves open. A listing that names four peptides and a total mass has told a buyer the identity of the contents and nothing about their proportions. A listing that publishes the nominal split has told them the specification. Only a listing that publishes an independent assay against a named lot has told them what is in the vial, and those three things are routinely presented as though they were interchangeable.

The table below separates them, because the difference between them is the difference between a claim and a measurement. The same reasoning applied more generally, what to ask a supplier for and what an answer is worth, is set out in how to vet a research peptide supplier.

Why a KLOW peptide lot needs four separate assays

A purity percentage answers one question: of the material present, how much of it was the intended compound. That question is well posed for a single-compound vial, where there is one intended compound. In a four-component blend it has to be asked four times, and a single number spanning all four is not a measurement of anything in particular.

This is where blends in this category are weakest. A listing that prints one purity figure for a four-part mixture has either assayed one component and let its number stand for the whole vial, or quoted a figure with no defined meaning. Neither of those says whether the 10mg of KPV named on the label is in the vial at all.

Three KLOW peptide lots are published here, each assayed by Freedom Diagnostics, an independent laboratory, with identity confirmed by LC-MS and content reported for every component. Put side by side, they make the argument for per-component reporting better than any paragraph can.

Read the overall column first and then ignore it. The three figures are 99.76%, 99.755% and 99.613%. They are near-identical, and the least informative part of any of the three documents. The per-component columns are where the lots differ, and they differ considerably. GHK-Cu comes in above its nominal 50mg on every lot, by 0.25mg on one and by 8.65mg on another. KPV comes in below its nominal 10mg on every lot. BPC-157 is below nominal on the newest lot and above it on the two older ones. None of that variation is visible in the overall percentage, and none of it exists at all on a certificate that treats a blend as one substance.

The two kinds of number are worth keeping apart, because they are answers to different questions. The nominal composition of 50, 10, 10 and 10 is the specification the blend is made to. The per-component content figures are a measurement of what a particular lot actually contained on a particular date. A document that publishes only the first has published a label. A document that publishes the second, component by component, against a stated lot code that can be checked by lot number, has published an analysis.

One row in that table also answers a question the certificates themselves raise. The oldest lot names its fourth line Thymosin Beta-4 where the two newer ones name it TB-500. That is a naming convention rather than a different material: TB-500 is the synthetic fragment Ac-LKKTETQ, and some laboratories report it under the name of the parent protein. The sequence and the mass on the line are the same either way, which is exactly the sort of thing worth checking before concluding that two certificates describe two different products.

The other lines on a blend certificate

Per-component content is the line that matters most on a blend, but it is not the only one, and the others are easier to read once it is clear what each is measuring. A certificate is a set of separate tests reported together, not a single verdict.

Identity and purity are the pair most often confused, because they are usually reported side by side and are produced by different instruments. Reversed-phase HPLC separates whatever is in the sample by how strongly each species sticks to a column, and measures how much of the total signal belongs to each peak. That is a purity measurement: it says what proportion of the material is the main species, and it says nothing about what that species is. Mass spectrometry weighs the molecule. That is an identity measurement: 1419.53 confirms BPC-157 in a way no retention time can, and 342.44 confirms KPV. A blend certificate needs both, and needs them four times over, because a peak in the right place with the wrong mass is exactly the failure a single overall purity figure would hide. The two methods are compared at greater length in the note on peptide purity testing.

Endotoxin is a separate test again, and it measures neither identity nor purity. It looks for bacterial endotoxin, a contaminant that survives processes that kill bacteria, and reports a pass or a level against a limit. Two of the three published KLOW lots carry an endotoxin result, passing on both replicates; the most recent lot's certificate does not include that test. That asymmetry is worth stating plainly rather than papering over, because an endotoxin line that is absent is different from one that failed, and a page that only ever mentions the tests it passed is not a documentation page.

Labelled content against net content is the last pairing worth understanding. Labelled content is what the vial claims. Net content is what was weighed. The two will not be identical, because lyophilization is a physical process with tolerances, and a vial filled to 80mg nominal may weigh in slightly above or below that. A certificate that reports both has given a reader something to check. A certificate that reports only the label has reported the packaging.

The net effect is that a four-component certificate carries more lines than a single-compound one, not because the laboratory is being thorough for its own sake, but because the questions multiply. One identity becomes four. One content figure becomes four. Appearance, endotoxin and overall purity stay single. The published certificates show exactly where that arithmetic lands.

What the blend becomes in solution

A lyophilized cake has no concentration. It has a mass, and it acquires a concentration only when a volume of solvent is chosen. For a single-compound vial that is one calculation. For KLOW peptide it is four, and they are locked to each other.

The arithmetic is simple and worth having written down, because the fixed ratio is the whole point. Whatever volume of bacteriostatic water is added, the four components arrive at concentrations in the same 5:1:1:1 proportion as the fill, and nothing done afterwards can change that. GHK-Cu will always be five times the concentration of each of the other three in the same solution. The table gives the figures for four volumes an 80mg vial is commonly taken to.

Two consequences follow. The first is that the total peptide concentration in a KLOW solution is high relative to a single-compound vial of the same volume, because 80mg is a large fill; a 10mg vial of BPC-157 taken to the same 2 mL sits at 5 mg/mL, where KLOW at 2 mL is 40 mg/mL of total peptide. The second is that the component concentrations cannot be separated. Choosing a volume that puts GHK-Cu at a given concentration puts the other three at a fifth of it, and that is the trade the blend makes.

The solvent itself is a material choice with documentation of its own. Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative, which is what makes a multi-draw container viable where plain sterile water is not; the difference is set out in bacteriostatic water for peptides, and the 3 mL and 10 mL containers carry their own specification. A blue solution is the expected result here, because free GHK is colourless and the copper complex is not, and clarity has to be judged against that background rather than against a colourless one.

How KLOW peptide is supplied, stored and handled

KLOW peptide is supplied as a blue lyophilized powder, soluble in bacteriostatic water, stored at −20°C for the long term and 2 to 8°C in use. Those conditions are no looser than for a single-compound vial. A blend can only be as stable as its least stable component, and four components are four opportunities for handling to be the thing that goes wrong.

That phrase deserves more than a sentence, because it is the one genuine handling difference between a blend and a single peptide. Each of the four has its own tolerance for temperature, for light and for time in solution. A vial containing all four is limited by whichever of the four is least tolerant on each of those axes, and nothing about the other three compensates. There is no such thing as a blend that is more robust than its components, only one that is easier to carry.

Three handling axes are worth separating, because they fail in different ways. Temperature is the obvious one: the dry cake is stable frozen for far longer than any solution is stable refrigerated, which is why the two storage figures differ rather than being a single number with a margin. Light is the second, and it is the one most often ignored: copper complexes are exactly the sort of species that ought to be kept dark, and a certificate that specifies protection from light has specified it for a reason. The third is freeze-thaw. Cycling a reconstituted solution through freezing and thawing is a different stress from holding it cold, and each cycle is applied to all four components at once. General practice for both states is covered in the note on how to store peptides.

The lyophilized state is doing the work in all of this. A dry cake is stable because the water that would let chemistry happen has been removed, which is why the storage figure for the powder is generous and the storage figure for a solution is not. What a lyophilized powder is, and what an intact cake should look like, is worth reading before judging a vial by eye.

The fixed ratio is the trade a blend makes. One vial and one set of handling decisions, in exchange for 50:10:10:10 and no way to vary it. Where a model system calls for a different proportion, or for one of the four on its own, separate vials are the only route.

Everything above describes material, composition, handling and documentation. KLOW peptide is supplied for in-vitro laboratory research use only, and nothing here describes use in humans or animals.

One vial or four

The blend and the separate components are two different propositions, and which one suits depends entirely on what is being asked of the material. The comparison is usually made on price, which is the axis where it is least interesting.

Three of the four are stocked here as single-compound vials at the same masses the blend carries: GHK-Cu at 50mg for $39.99, BPC-157 at 10mg for $59.99 and TB-500 at 10mg for $84.99, which is $184.97 for the three. The equivalent three-component blend, GLOW at 70mg, is $119.99. KLOW at 80mg is $139.99, or $1.75 per milligram of peptide. But the four-vial comparison cannot actually be completed from this catalogue, because KPV is not stocked on its own. Inside KLOW is the only way to obtain it here.

Price is the smallest part of the difference. The real distinctions are about control and attribution, and they run in both directions.

The one-vial case: fewer objects to handle, one reconstitution rather than four, one set of storage decisions, one certificate to read, and a composition that cannot drift between preparations because it was fixed at the fill. The four-vial case: every proportion chosen rather than inherited, each component documented on a certificate of its own, and the ability to remove one variable from a system without disturbing the other three. Nothing in a blend can be varied, removed or attributed after the fact, and that is a genuine cost rather than a rhetorical one.

KLOW, GLOW and the BPC-157 + TB-500 pair: what the names mean

None of these names is a chemical name. They are product names for particular combinations, and the only thing separating them is what is in the vial, so it is worth writing the family out once.

GLOW is the like-for-like comparison to KLOW: the same three-component base at 70mg, without KPV. The whole difference between the two products is 10mg of the tripeptide this article has spent most of its length on, and the corresponding fourth line on the certificate. The two are set against each other in GLOW vs KLOW peptide blends.

The third combination in this corner of the category is BPC-157 and TB-500 together, without the copper tripeptide. That pairing is stocked here as the Repair Reference Panel, which is the same two compounds supplied as separate documented vials rather than co-lyophilized into one cake. That is a distinction worth holding onto, because a panel of two vials and a blend of two peptides are not the same object even when the contents are named identically. A blend has one certificate and one ratio; a panel has two of each.

The relationship between all three is additive and easy to state. The first is the BPC-157 and TB-500 pair. GLOW is that pair plus GHK-Cu. KLOW is GLOW plus KPV. Every step up adds a named component, a line on the certificate and mass to the fill, and no step changes the components already there.

Spellings and formattings vary: KLOW, K-LOW, KLOW 80, KLOW Blend. None of them means anything different. The only variation that matters is the split, and that is a property of the supplier rather than of the name.

Where this sits with regulators

This is the part most pages in the category leave out, and it is the shortest to write accurately. KLOW peptide is not an approved drug. It has not been evaluated by the FDA, it is not the subject of an approved application, and none of its four components is an approved drug product either. GHK-Cu, KPV, BPC-157 and TB-500 are research compounds. There is no approval attached to any of them for the purposes people search for, and no amount of laboratory documentation creates one.

A research chemical is also not the same thing as a compounded preparation. Compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act prepare medicines for identified patients or for office stock under a specific regulatory framework, with the oversight that framework carries. Material supplied for in-vitro laboratory research sits outside that framework entirely. The two are sometimes discussed as though they were points on a spectrum; they are separate categories with separate rules, and a research vial does not become a compounded preparation because it has a certificate.

What a certificate does establish is narrower and worth stating precisely: that a named independent laboratory, on a named date, measured the identity and content of the material in a named lot and recorded the result. That is a statement about a batch of chemical. It is not an approval, not an endorsement, and not a claim about anything beyond the analysis performed.

There is no published study of this four-component combination. Each component has its own preclinical and in-vitro literature, in model systems: GHK-Cu going back to Pickart and Thaler in 1973, KPV to work published in Gastroenterology, BPC-157 and TB-500 each with their own bodies of source work. That literature belongs to the individual molecules rather than to the blend. A combination is not the sum of the literature on its parts, and describing it that way would be a claim nobody has tested.

KLOW peptide is supplied here for in-vitro laboratory research use only. It is not for human or veterinary use, not for diagnostic use, and not for any form of administration.